Adaptimmune Therapeutics plc (ADAP) EPS Estimated At $-0.25; Passport Capital Lifted Affiliated Managers Group (AMG) Position By $372,897

February 20, 2018 - By Richard Conner

Analysts expect Adaptimmune Therapeutics plc (NASDAQ:ADAP) to report $-0.25 EPS on March, 12.They anticipate $0.03 EPS change or 13.64% from last quarter’s $-0.22 EPS. The stock increased 1.29% or $0.11 during the last trading session, reaching $8.62. About 301,201 shares traded. Adaptimmune Therapeutics plc (NASDAQ:ADAP) has declined 43.56% since February 20, 2017 and is downtrending. It has underperformed by 60.26% the S&P500.

Passport Capital Llc increased Affiliated Managers Group (AMG) stake by 6.13% reported in 2017Q3 SEC filing. Passport Capital Llc acquired 1,973 shares as Affiliated Managers Group (AMG)’s stock declined 9.34%. The Passport Capital Llc holds 34,156 shares with $6.48M value, up from 32,183 last quarter. Affiliated Managers Group now has $10.66 billion valuation. The stock increased 0.79% or $1.5 during the last trading session, reaching $191.79. About 366,922 shares traded or 2.07% up from the average. Affiliated Managers Group, Inc. (NYSE:AMG) has declined 5.60% since February 20, 2017 and is downtrending. It has underperformed by 22.30% the S&P500.

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary SPEAR T-cell platform. The company has market cap of $807.58 million. The Company’s platform enables to identify cancer targets; find and genetically engineer T-cell receptors ; and produce TCR therapeutic candidates for administration to patients. It currently has negative earnings. The company's lead program includes NY-ESO-1 and LAGE-1a cancer antigens, which are in Phase I/II clinical trials for patients with solid tumors, as well as hematological cancer types, including synovial sarcoma, multiple myeloma, non-small cell lung cancer (NSCLC), and ovarian cancer; and pilot trial for myxoid round cell liposarcoma.

Among 5 analysts covering Adaptimmune Therapeutics PLC (NASDAQ:ADAP), 3 have Buy rating, 1 Sell and 1 Hold. Therefore 60% are positive. Adaptimmune Therapeutics PLC had 5 analyst reports since February 25, 2016 according to SRatingsIntel. The stock has “Buy” rating by Citigroup on Thursday, February 25. Bank of America downgraded the shares of ADAP in report on Monday, October 24 to “Underperform” rating. As per Saturday, November 11, the company rating was maintained by SunTrust. On Tuesday, June 6 the stock rating was maintained by Cowen & Co with “Buy”.

Investors sentiment increased to 0.91 in Q3 2017. Its up 0.01, from 0.9 in 2017Q2. It improved, as 34 investors sold AMG shares while 158 reduced holdings. 50 funds opened positions while 125 raised stakes. 49.56 million shares or 1.61% less from 50.37 million shares in 2017Q2 were reported. Chevy Chase Trust Hldg holds 48,806 shares or 0.04% of its portfolio. North Star Asset Mgmt holds 1.53% of its portfolio in Affiliated Managers Group, Inc. (NYSE:AMG) for 88,323 shares. Rampart Inv Mgmt Ltd has invested 0.04% of its portfolio in Affiliated Managers Group, Inc. (NYSE:AMG). Kentucky Retirement Insur Tru Fund holds 1,497 shares. Benjamin F Edwards & Incorporated reported 0% of its portfolio in Affiliated Managers Group, Inc. (NYSE:AMG). Bb&T Corp holds 7,509 shares. Fuller And Thaler Asset Mngmt owns 300 shares. Bruni J V & has 8.11% invested in Affiliated Managers Group, Inc. (NYSE:AMG). Asset One Limited has 83,814 shares. Liberty Mutual Asset Mngmt has 0.02% invested in Affiliated Managers Group, Inc. (NYSE:AMG). Gateway Investment Advisers Limited Liability Corporation has 74,075 shares for 0.12% of their portfolio. Mai Cap Management stated it has 2,525 shares. Ghp Inv Advisors owns 1,144 shares. Zurcher Kantonalbank (Zurich Cantonalbank) holds 0.02% in Affiliated Managers Group, Inc. (NYSE:AMG) or 10,797 shares. Raymond James Fin Svcs Advisors reported 0% in Affiliated Managers Group, Inc. (NYSE:AMG).

Among 10 analysts covering Affiliated Managers Group (NYSE:AMG), 8 have Buy rating, 0 Sell and 2 Hold. Therefore 80% are positive. Affiliated Managers Group had 48 analyst reports since August 9, 2015 according to SRatingsIntel. Deutsche Bank maintained Affiliated Managers Group, Inc. (NYSE:AMG) rating on Friday, August 5. Deutsche Bank has “Buy” rating and $183 target. The firm has “Buy” rating by Deutsche Bank given on Monday, July 18. The firm has “Outperform” rating given on Wednesday, February 3 by Barrington Research. Deutsche Bank maintained Affiliated Managers Group, Inc. (NYSE:AMG) on Wednesday, October 5 with “Buy” rating. The firm has “Buy” rating given on Wednesday, January 10 by Jefferies. On Friday, January 8 the stock rating was maintained by Deutsche Bank with “Buy”. Deutsche Bank maintained it with “Buy” rating and $246 target in Friday, September 18 report. As per Friday, September 1, the company rating was maintained by Keefe Bruyette & Woods. Deutsche Bank downgraded Affiliated Managers Group, Inc. (NYSE:AMG) rating on Friday, November 4. Deutsche Bank has “Hold” rating and $132 target. Jefferies maintained Affiliated Managers Group, Inc. (NYSE:AMG) rating on Thursday, August 17. Jefferies has “Buy” rating and $200.0 target.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>